Home / Drug shortages / Irinotecan Hydrochloride Injection

Irinotecan Hydrochloride Injection — FDA Drug Shortage

To Be Discontinued — Teva Pharmaceuticals USA, Inc.

The FDA lists a drug shortage record for Irinotecan Hydrochloride Injection (injection) from Teva Pharmaceuticals USA, Inc. with status To Be Discontinued. The shortage was first posted on 08/04/2025.

Shortage Details

Status
To Be Discontinued
Company
Teva Pharmaceuticals USA, Inc.
Package NDC
45963-614-51
Dosage Form
Injection
Presentation
Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-51)
Initial Posting
08/04/2025
Revised Date

FDA data resources